Mohamed Issa serves as Executive Vice President and Head of U.S. Commercial at Incyte Corporation, a leading biopharmaceutical company focused on oncology and inflammation. In this role, he oversees the company's entire U.S. commercial operations, including sales, marketing, market access, and medical affairs for Incyte's flagship portfolio, such as Jakafi, Opzelura, and Pemazyre. Under his leadership, Incyte has expanded its commercial footprint, driving significant revenue growth and enhancing patient access to innovative therapies. Issa brings over 25 years of experience in the pharmaceutical industry, with a proven track record in commercial strategy and execution. Prior to joining Incyte in 2021, he held senior leadership positions at Bristol Myers Squibb, where he served as Vice President of U.S. Oncology Commercial, spearheading the launch of multiple blockbuster therapies and achieving double-digit market share gains. Earlier in his career, he progressed through roles at Pfizer and AstraZeneca, building expertise in hematology, solid tumors, and immunology. His achievements include orchestrating high-impact product launches that generated billions in annual sales and fostering cross-functional teams to navigate complex payer landscapes. A graduate of the University of Cairo with an MBA from Columbia Business School, Issa is recognized for his strategic vision and commitment to data-driven innovation, positioning Incyte for sustained leadership in precision medicine.